Price
Target price
€49.20
€49.20
1.650%
0.8
1.650%
€54.34
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Protagonist Therapeutics Inc Stock
There is an upward development for Protagonist Therapeutics Inc compared to yesterday, with an increase of €0.80 (1.650%).
With 24 Buy predictions and 1 Sell predictions Protagonist Therapeutics Inc is one of the favorites of our community.
As a result the target price of 54 € shows a slightly positive potential of 9.76% compared to the current price of 49.2 € for Protagonist Therapeutics Inc.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Protagonist Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Protagonist Therapeutics Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
C******** o* t** e**********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Comments
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "outperform" rating re-affirmed by analysts at Citigroup Inc..
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $72.00 price target on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
News
Protagonist (PTGX) Q2 Revenue Falls 26%
Protagonist Therapeutics (NASDAQ:PTGX), a clinical-stage biotechnology company developing peptide-based therapies for blood and immune diseases, released second quarter results on August 6, 2025
